Evidence map›Paper›PMID 42872010›Full record

ArticleACS pharmacology & translational science2026

A Human Glucoregulatory Model for the Rational Design and Evaluation of Diabetes Therapeutics.

Marco Machado, Sungyun Yang, Ali A Alizadehmojarad, Michael S Strano

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marco MachadoDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Sungyun YangDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID https://orcid.org/0000-0002-3728-9544
Ali A AlizadehmojaradDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID https://orcid.org/0000-0001-6806-5415
Michael S StranoDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID https://orcid.org/0000-0003-2944-808X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus remains a leading cause of morbidity worldwide, motivating the development of novel diabetes therapeutics. Computational glucoregulatory models that incorporate biochemical signaling and mechanisms have shown utility for preclinical evaluation and even the rational design of such interventions, potentially reducing the need for animal experimentation. In this work, we expand upon our IM

Indexed as

diabetesglucoregulatory modelingglucose-responsive glucagonpharmacodynamicsrational therapeutic design

Identifiers

PMID42872010
PMCPMC13659854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.